JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph has maintained an Underweight rating on Enanta Pharma (NASDAQ: ENTA) and lowered the price target from $12 to $11.

February 08, 2024 | 9:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan has maintained an Underweight rating on Enanta Pharma and reduced the price target from $12 to $11.
The reduction in price target by a major financial institution like JP Morgan, accompanied by an Underweight rating, suggests a bearish outlook on the stock. This could lead to a decrease in investor confidence and potentially lower stock prices in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100